Semantic Dementia Clinical Trials 2023

Semantic Dementia Clinical Trials 2023

Semantic Dementia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in semantic dementia clinical trials today.

Trials for FTD Patients

Trials for Primary Progressive Aphasia Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to semantic dementia

What are the top hospitals conducting semantic dementia research?

When it comes to the challenging realm of semantic dementia, several top hospitals are taking remarkable strides in clinical trials. In Philadelphia, the University of Pennsylvania is leading the charge with seven ongoing trials focused specifically on this condition. Their dedication to understanding semantic dementia extends back to 2003 when they conducted their first recorded trial. Meanwhile, at Mayo Clinic in Rochester, researchers are vigorously pursuing knowledge by engaging in six active trials and have previously completed 15 investigations since their inaugural study in 2008.

Boston's Massachusetts General Hospital also stands out for its commitment to tackling semantic dementia with four ongoing clinical trials and a history of ten previous studies dating back only a decade ago to2011 . The renowned Johns Hopkins Hospital in Baltimore is equally invested in advancing our understanding of this complex disorder, currently conducting four active trials while having completed five prior investigations since initiating their first trial backin 2007.

Additionally contributing significant research efforts is the University of California San Francisco (UCSF) where three active clinical trials are underway as part of their mission to combat semantic dementia. Although relatively new compared to other institutions mentioned here; however UCSF has swiftly emerged as a major player through achieving seven all-time experimental endeavors thus far, beginning only recently fromtheir initial trial recording as recent as2014.

These esteemed hospitals not only provide hope for those affected by semantic dementia but also demonstrate an unwavering commitment towards unraveling the mysteries surrounding this neurodegenerative disease. The collective work undertaken at these pioneering medical institutions sets us firmly on course towards potential breakthroughs that may ultimately improve lives around the world impacted by this devastating condition.

Which are the best cities for semantic dementia clinical trials?

When it comes to semantic dementia clinical trials, several cities emerge as leading hubs for research and development. San Francisco, California takes the lead with 11 active trials investigating treatments like AL001, Care Ecosystem, and Cohort 2A - [18F]RP-115 in age-matched controls. Philadelphia, Pennsylvania closely follows with 10 ongoing studies focused on interventions such as AL001, Online training site, and Immediate treatment group with Low-Intensity Prompts. Rochester, Minnesota also plays a significant role in this field with 9 active trials exploring options like AL001 and Pittsburgh Compound B (C-11 PiB). These cities provide individuals affected by semantic dementia access to cutting-edge clinical trials that drive progress in understanding and treating this condition.

Which are the top treatments for semantic dementia being explored in clinical trials?

The search for effective treatments in the realm of semantic dementia is ongoing, with several promising options currently being explored in clinical trials. AL001 stands out as a leading candidate, with two active trials dedicated to investigating its potential benefits. This treatment has gained traction since its introduction in 2018 and has contributed to three all-time clinical trials focused on semantic dementia. Additionally, bilateral subgenual cingulate deep brain stimulation (SGC DBS) and Care Ecosystem are emerging contenders, each with one active trial and one all-time trial specifically targeting semantic dementia since their listing in 2023. These innovative approaches offer hope for individuals grappling with this challenging condition.

What are the most recent clinical trials for semantic dementia?

Exciting progress is being made in the realm of semantic dementia with recent clinical trials offering new insights and potential treatments. One such trial focuses on remotely supervised transcranial direct current stimulation (tdcs) paired with word-naming practice for individuals experiencing semantic dementia. This Phase 2 study, which became available on 11/1/2022, explores the efficacy of this intervention in improving language abilities and cognitive function. Additionally, a Phase 3 trial investigates the use of N-Acetyl-L-Leucine as a possible treatment for semantic dementia, aiming to assess its impact on disease progression and symptom management. Lastly, a Phase 1 trial conducted on Verdiperstat examines the safety profile and tolerability of this drug in patients with semantic dementia. These ongoing studies offer hope for improved understanding and potential therapies for those affected by this condition.

What semantic dementia clinical trials were recently completed?

Columbia University recently completed a clinical trial in January 2017, investigating the potential of Lithium Carbonate as a treatment for semantic dementia. This study marks an important step forward in understanding and addressing this debilitating condition.